SynthesisProstate cancer and prostatic diseases2024
Comparison of
Synthesis in Prostate cancer and prostatic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Comparative Detection Performance of PSMA and Non-PSMA PET Tracers in Recurrent and Primary Prostate Cancer: A Systematic Review and Network Meta-Analysis.Clinical nuclear medicine · 2026Pooled it
- Detection rate of [Frontiers in medicine · 2026Pooled it
- Oligometastatic prostate cancer - bridging the gap between localized and metastatic disease.Nature reviews. Urology · 2026Review
- Article
- New paradigm of q-CAR drug development targeting disease-specific protein conformations.npj drug discovery · 2026Review
- PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making.Cancers · 2026Review
- SuFEx and macrocyclic chelation define orthogonal reactivity domains enabling isotopically versatile radiopharmaceuticals from a single peptide precursor.bioRxiv : the preprint server for biology · 2026Article
- Deep learning algorithm assisting diagnosis of prostate cancer extracapsular extension based on [Prostate cancer and prostatic diseases · 2026Article
- Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer.Cancers · 2026Article
- PET-based risk stratification for adverse events under [European journal of nuclear medicine and molecular imaging · 2026Article
- PSMA PET/CT for the detection of prostate cancer biochemical recurrence after primary radiation therapy: is it time to review the Phoenix criteria?European journal of nuclear medicine and molecular imaging · 2026Article
- Diagnostic Accuracy of [Cancers · 2026Article
- Head-to-head comparison betweenJournal of translational medicine · 2026Article
- Integrating Multiparametric MRI and PSMA PET Imaging in Prostate Cancer: Toward a Unified Diagnostic and Risk-Stratification Paradigm.Medicina (Kaunas, Lithuania) · 2026Review
- Impact of local tumor-to-background uptake ratio on PET metabolic response assessment.Radiation protection dosimetry · 2026Article
- Prostate specific membrane antigen (PSMA) as a biomarker in early and localized advanced prostate cancer: a narrative review.The Canadian journal of urology · 2026Review
- Quantitative characterization ofMolecular imaging and radionuclide therapy · 2026Article
- Beyond discovery: are we understanding PET tracers as fast as we invent them? a critical review.EJNMMI research · 2026Review
- The role of multimodality imaging in selection, response assessment, and follow-up of patients receivingInsights into imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) has become an increasingly established imaging modality in the staging of prostate cancer (PCa). Numerous PSMA-based tracers are currently available, however, there is a lack of consensus on the optimal radiotracer(s) for PSMA PET/CT. This study aims to investigate whether Fluorine-18 (
methodsA critical review of MEDLINE, EMBASE, PubMed and Web of Science databases was performed in May 2023 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Studies that directly compared
resultsTwenty-four studies were analysed. [
conclusions[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.